Literature DB >> 32749748

Aurantio-obtusin improves obesity and insulin resistance induced by high-fat diet in obese mice.

Cong-Ying Guo1,2, Wei-Tao Liao1,2, Rui-Jin Qiu3, Dan-Shui Zhou1,2, Wei-Ju Ni1,2, Cui-Ping Yu3, Yu Zeng1,2.   

Abstract

Aurantio-obtusin (AUR) is the main bioactive compound among the anthraquinones, from Cassia seed extract. This study was conducted to identify whether AUR could improve obesity and insulin resistance, induced by a high-fat diet in obese mice. Mice were fed a high-fat diet for 6 weeks and were then assigned to the high-fat diet (HFD) control group, the AUR 5 mg/kg group, or the AUR 10 mg/kg group. AUR improves glucose by activating the expression of PI3K, Akt and GLUT4, GLUT2. AUR altered the expression levels of several lipid metabolism-related and adipokine genes. AUR decreased the mRNA expression of PPAR-γ, FAS and increased the mRNA expression of PPAR-α in liver. AUR lowered SREBP-1c, FAS, SCD-1, inflammatory cytokines, and increased the expression of PPAR-γ, PPAR-α, CPT-1, and adiponectin in white adipose tissue (WAT). AUR docking with the insulin receptor showed that the residues of the insulin receptor, ectodomain, were the same as those around the emodin. The effect of AUR may be elicited by regulating the activity of the insulin signaling pathway, expression of lipid metabolism-related genes, and expression of inflammatory cytokine markers to improve adiposity, insulin resistance, and dyslipidemia.
© 2020 John Wiley & Sons, Ltd.

Entities:  

Keywords:  aurantio-obtusin; high-fat diet induced obese mice; insulin resistance; molecular-docking

Mesh:

Substances:

Year:  2020        PMID: 32749748     DOI: 10.1002/ptr.6805

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  2 in total

1.  Aurantio-Obtusin Attenuates Non-Alcoholic Fatty Liver Disease Through AMPK-Mediated Autophagy and Fatty Acid Oxidation Pathways.

Authors:  Fei Zhou; Mingning Ding; Yiqing Gu; Guifang Fan; Chuanyang Liu; Yijie Li; Rong Sun; Jianzhi Wu; Jianchao Li; Xiaoyong Xue; Hongjuan Li; Xiaojiaoyang Li
Journal:  Front Pharmacol       Date:  2022-01-11       Impact factor: 5.810

Review 2.  Recent Advances in the Treatment of Insulin Resistance Targeting Molecular and Metabolic Pathways: Fighting a Losing Battle?

Authors:  Marta Wolosowicz; Slawomir Prokopiuk; Tomasz W Kaminski
Journal:  Medicina (Kaunas)       Date:  2022-03-25       Impact factor: 2.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.